Cyclin dependent kinase 1 inhibitors: A review of recent progress

Current Medicinal Chemistry

Volumn 18, Issue 13, 2011, Pages 2025-2043

  Wang, Q ^a   Su, L ^a   Liu, N ^a   Zhang, L ^a   Xu, W ^a   Fang, H ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cancer therapy agents; CDK1 inhibitors; Cell cycle; Cyclin dependent kinases; G2 phase; Mitosis; Tumor

Indexed keywords

2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 2 AMINO 4 (7 AZAINDOL 3 YL)PYRIMIDINE; 2 BENZYLIDENE 4,6 DIHYDROXY 7 (1 METHYLPIPERIDIN 4 YL)BENZOFURAN 3 ONE; 3 BENZOFURANONE DERIVATIVE; 3 HYDROXYCHROMONE DERIVATIVE; 4 (1 ISOPROPYL 2 METHYLIMIDAZOL 5 YL) 2 (4 METHYLSULPHONYLANILINO)PYRIMIDINE; AZD 5438; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 1 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; INDOLIN 2 ONE; MITOXANTRONE; OXALIPLATIN; OXOINDOLE; PROTEIN P21; PROTEIN P27; PURINE DERIVATIVE; PYRAZOLO[3,4 B]PYRIDINE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; R 547; STAUROSPORINE; THIOFLAVOPIRIDOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTINUOUS INFUSION; DEPHOSPHORYLATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; HYPERPHOSPHATEMIA; HYPONATREMIA; MITOSIS; MOLECULAR DOCKING; MOLECULAR INTERACTION; NAUSEA; NEOPLASM; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

AMINO ACID SEQUENCE; ANIMALS; CDC2 PROTEIN KINASE; CELL LINE; HUMANS; MITOSIS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 79957937959     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795590110     Document Type: Review

References (186)

1. Vermeulen, K.; Van Bockstaele, D.R.; Berneman, Z.N., The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif., 2003, 36, 131-149. (Pubitemid 36808270)
2. Toogood, P.L., Cyclin-dependent kinase inhibitors for treating cancer. Med. Res. Rev., 2001, 21, 487-498. (Pubitemid 32959238)
3. Malumbres, M.; Barbacid, M., Mammalian cyclin-dependent kinases. Trends Biochem. Sci., 2005, 30, 630-641. (Pubitemid 41540083)
4. Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J.R., CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci., 2008, 29, 16-21.
5. Liu, N.; Fang, H.; Li, Y.; Xu, W., Recent research in selective cyclindependent kinase 4 inhibitors for anti-cancer treatment. Curr. Med. Chem., 2009, 16, 4869-4888.
6. Akli, S.; Keyomarsi, K., Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol. Ther., 2003, 2, S38-47.
7. Bashir, T.; Pagano, M., Cdk1: the dominant sibling of Cdk2. Nat. Cell Biol., 2005, 7, 779-781. (Pubitemid 41079049)
8. Errico, A.; Deshmukh, K.; Tanaka, Y.; Pozniakovsky, A.; Hunt, T., Identification of substrates for cyclin dependent kinases. Adv. Enzyme Regul., 2010, 50, 375-399.
9. Santamaria, D.; Barriere, C.; Cerqueira, A.; Hunt, S.; Tardy, C.; Newton, K.; Caceres, J.F.; Dubus, P.; Malumbres, M.; Barbacid, M., Cdk1 is sufficient to drive the mammalian cell cycle. Nature, 2007, 448, 811-815. (Pubitemid 47266342)
10. Barriere, C.; Santamaria, D.; Cerqueira, A.; Galan, J.; Martin, A.; Ortega, S.; Malumbres, M.; Dubus, P.; Barbacid, M., Mice thrive without Cdk4 and Cdk2. Mol. Oncol., 2007, 1, 72-83. (Pubitemid 46776620)
11. Berthet, C.; Aleem, E.; Coppola, V.; Tessarollo, L.; Kaldis, P., Cdk2 knockout mice are viable. Curr. Biol., 2003, 13, 1775-1785. (Pubitemid 37274109)
12. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; Sotillo, R.; Barbero, J.L.; Malumbres, M.; Barbacid, M., Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet., 2003, 35, 25-31. (Pubitemid 37048592)
13. Malumbres, M.; Barbacid, M., Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 2009, 9, 153-166.
14. Migone, F.; Deinnocentes, P.; Smith, B.F.; Bird, R.C., Alterations in CDK1 expression and nuclear/nucleolar localization following induction in a spontaneous canine mammary cancer model. J. Cell Biochem., 2006, 98, 504-518. (Pubitemid 43739344)
15. Nakayama, S.; Torikoshi, Y.; Takahashi, T.; Yoshida, T.; Sudo, T.; Matsushima, T.; Kawasaki, Y.; Katayama, A.; Gohda, K.; Hortobagyi, G.N.; Noguchi, S.; Sakai, T.; Ishihara, H.; Ueno, N.T., Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res., 2009, 11, R12.
16. Sharma, P.S.; Sharma, R.; Tyagi, R., Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr. Cancer Drug Targets, 2008, 8, 53-75. (Pubitemid 351237910)
17. Knockaert, M.; Greengard, P.; Meijer, L., Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci., 2002, 23, 417-425. (Pubitemid 35247771)
18. Canduri, F.; Uchoa, H.B.; de Azevedo, W.F., Jr., Molecular models of cyclin-dependent kinase 1 complexed with inhibitors. Biochem. Biophys. Res. Commun., 2004, 324, 661-666. (Pubitemid 39345567)
19. Otyepka, M.; Krystof, V.; Havlicek, L.; Siglerova, V.; Strnad, M.; Koca, J., Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J. Med. Chem., 2000, 43, 2506-2513. (Pubitemid 30437132)
20. De Bondt, H.L.; Rosenblatt, J.; Jancarik, J.; Jones, H.D.; Morgan, D.O.; Kim, S.H., Crystal structure of cyclin-dependent kinase 2. Nature, 1993, 363, 595-602. (Pubitemid 23227617)
21. Jeffrey, P.D.; Russo, A.A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N.P., Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature, 1995, 376, 313-320.
22. McGrath, C.F.; Pattabiraman, N.; Kellogg, G.E.; Lemcke, T.; Kunick, C.; Sausville, E.A.; Zaharevitz, D.W.; Gussio, R., Homology model of the CDK1/cyclin B complex. J. Biomol. Struct. Dyn., 2005, 22, 493-502. (Pubitemid 40344240)
23. Zhang, L.; Zhu, H.; Wang, Q.; Fang, H.; Xu, W.; Li, M., Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1. J. Mol. Model, 2011, 17, 219-226.
24. Fousteris, M.A.; Papakyriakou, A.; Koutsourea, A.; Manioudaki, M.; Lampropoulou, E.; Papadimitriou, E.; Spyroulias, G.A.; Nikolaropoulos, S.S., Pyrrolo[2,3-a]carbazoles as potential cyclin dependent kinase 1 (CDK1) Inhibitors. Synthesis, biological evaluation, and binding mode through docking simulations. J. Med. Chem., 2008, 51, 1048-1052. (Pubitemid 351304713)
25. Booher, R.; Beach, D., Interaction between cdc13+ and cdc2+ in the control of mitosis in fission yeast; dissociation of the G1 and G2 roles of the cdc2+ protein kinase. EMBO J., 1987, 6, 3441-3447.
26. Lee, M.G.; Nurse, P., Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature, 1987, 327, 31-35. (Pubitemid 17063755)
27. Picard, A.; Labbe, J.C.; Barakat, H.; Cavadore, J.C.; Doree, M., Okadaic acid mimics a nuclear component required for cyclin B-cdc2 kinase microinjection to drive starfish oocytes into M phase. J. Cell Biol., 1991, 115, 337-344. (Pubitemid 21926031)
28. Riabowol, K.; Draetta, G.; Brizuela, L.; Vandre, D.; Beach, D., The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell, 1989, 57, 393-401. (Pubitemid 19126273)
29. van den Heuvel, S.; Harlow, E., Distinct roles for cyclin-dependent kinases in cell cycle control. Science, 1993, 262, 2050-2054. (Pubitemid 24041887)
30. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J.P.; Sedivy, J.M.; Kinzler, K.W.; Vogelstein, B., Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science, 1998, 282, 1497-1501. (Pubitemid 28538613)
31. Chen, J.; Jackson, P.K.; Kirschner, M.W.; Dutta, A., Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 1995, 374, 386-388.
32. Murray, A., Cyclin ubiquitination: the destructive end of mitosis. Cell, 1995, 81, 149-152.
33. Darzynkiewicz, Z.; Smolewski, P.; Bedner, E., Use of flow and laser scanning cytometry to study mechanisms regulating cell cycle and controlling cell death. Clin. Lab. Med., 2001, 21, 857-873. (Pubitemid 33127031)
34. Pines, J.; Hunter, T., Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J. Cell Biol., 1991, 115, 1-17. (Pubitemid 21909889)
35. Strausfeld, U.P.; Howell, M.; Descombes, P.; Chevalier, S.; Rempel, R.E.; Adamczewski, J.; Maller, J.L.; Hunt, T.; Blow, J.J., Both cyclin A and cyclin E have S-phase promoting (SPF) activity in Xenopus egg extracts. J. Cell Sci., 1996, 109 ( Pt 6), 1555-1563. (Pubitemid 26190504)
36. Clute, P.; Pines, J., Temporal and spatial control of cyclin B1 destruction in metaphase. Nat. Cell Biol., 1999, 1, 82-87. (Pubitemid 129501948)
37. Nurse, P.; Bissett, Y., Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast. Nature, 1981, 292, 558-560. (Pubitemid 11023994)
38. Lorincz, A.T.; Reed, S.I., Primary structure homology between the product of yeast cell division control gene CDC28 and vertebrate oncogenes. Nature, 1984, 307, 183-185. (Pubitemid 14132910)
39. Reed, S.I.; de Barros Lopes, M.A.; Ferguson, J.; Hadwiger, J.A.; Ho, J.Y.; Horwitz, R.; Jones, C.A.; Lorincz, A.T.; Mendenhall, M.D.; Peterson, T.A.; et al., Genetic and molecular analysis of division control in yeast. Cold Spring Harb. Symp. Quant Biol., 1985, 50, 627-634.
40. Satyanarayana, A.; Hilton, M.B.; Kaldis, P., p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol. Biol. Cell, 2008, 19, 65-77. (Pubitemid 351186133)
41. Castedo, M.; Perfettini, J.L.; Roumier, T.; Kroemer, G., Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ., 2002, 9, 1287-1293. (Pubitemid 36097698)
42. Yun, J.; Chae, H.D.; Choy, H.E.; Chung, J.; Yoo, H.S.; Han, M.H.; Shin, D.Y., p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J. Biol. Chem., 1999, 274, 29677-29682.
43. Taylor, W.R.; DePrimo, S.E.; Agarwal, A.; Agarwal, M.L.; Schonthal, A.H.; Katula, K.S.; Stark, G.R., Mechanisms of G2 arrest in response to overexpression of p53. Mol. Biol. Cell, 1999, 10, 3607-3622. (Pubitemid 29534013)
44. Badie, C.; Itzhaki, J.E.; Sullivan, M.J.; Carpenter, A.J.; Porter, A.C., Repression of CDK1 and other genes with CDE and CHR promoter elements during DNA damage-induced G(2)/M arrest in human cells. Mol. Cell Biol., 2000, 20, 2358-2366. (Pubitemid 30152044)
45. Maity, A.; McKenna, W.G.; Muschel, R.J., Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO J., 1995, 14, 603-609.
46. Russell, P.; Nurse, P., Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell, 1987, 49, 559-567.
47. Parker, L.L.; Atherton-Fessler, S.; Piwnica-Worms, H., p107wee1 is a dualspecificity kinase that phosphorylates p34cdc2 on tyrosine 15. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 2917-2921.
48. Solomon, M.J.; Lee, T.; Kirschner, M.W., Role of phosphorylation in p34cdc2 activation: identification of an activating kinase. Mol. Biol. Cell, 1992, 3, 13-27. (Pubitemid 23094249)
49. Mueller, P.R.; Coleman, T.R.; Kumagai, A.; Dunphy, W.G., Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science, 1995, 270, 86-90.
50. Hoffmann, I., The role of Cdc25 phosphatases in cell cycle checkpoints. Protoplasma, 2000, 211, 8-11. (Pubitemid 30187840)
51. Porter, L.A.; Donoghue, D.J., Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog. Cell Cycle Res., 2003, 5, 335-347.
52. Gautier, J.; Solomon, M.J.; Booher, R.N.; Bazan, J.F.; Kirschner, M.W., cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell, 1991, 67, 197-211. (Pubitemid 121001436)
53. Honda, R.; Ohba, Y.; Nagata, A.; Okayama, H.; Yasuda, H., Dephosphorylation of human p34cdc2 kinase on both Thr-14 and Tyr-15 by human cdc25B phosphatase. FEBS Lett., 1993, 318, 331-334. (Pubitemid 23071764)
54. Izumi, T.; Maller, J.L., Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol. Biol. Cell, 1993, 4, 1337-1350. (Pubitemid 24045763)
55. Peng, C.Y.; Graves, P.R.; Thoma, R.S.; Wu, Z.; Shaw, A.S.; Piwnica- Worms, H., Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science, 1997, 277, 1501-1505. (Pubitemid 27449237)
56. Roshak, A.K.; Capper, E.A.; Imburgia, C.; Fornwald, J.; Scott, G.; Marshall, L.A., The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal, 2000, 12, 405-411. (Pubitemid 30417604)
57. Bulavin, D.V.; Higashimoto, Y.; Demidenko, Z.N.; Meek, S.; Graves, P.; Phillips, C.; Zhao, H.; Moody, S.A.; Appella, E.; Piwnica-Worms, H.; Fornace, A.J., Jr., Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat. Cell Biol., 2003, 5, 545-551. (Pubitemid 36781089)
58. Boutros, R.; Dozier, C.; Ducommun, B., The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol., 2006, 18, 185-191. (Pubitemid 43375887)
59. Toyoshima, H.; Hunter, T., p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 1994, 78, 67-74. (Pubitemid 24228301)
60. Smits, V.A.; Klompmaker, R.; Vallenius, T.; Rijksen, G.; Makela, T.P.; Medema, R.H., p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J. Biol. Chem., 2000, 275, 30638-30643.
61. Foijer, F.; Wolthuis, R.M.; Doodeman, V.; Medema, R.H.; te Riele, H., Mitogen requirement for cell cycle progression in the absence of pocket protein activity. Cancer Cell, 2005, 8, 455-466. (Pubitemid 41773449)
62. Gillis, L.D.; Leidal, A.M.; Hill, R.; Lee, P.W., p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage. Cell Cycle, 2009, 8, 253-256.
63. Royou, A.; McCusker, D.; Kellogg, D.R.; Sullivan, W., Grapes(Chk1) prevents nuclear CDK1 activation by delaying cyclin B nuclear accumulation. J. Cell Biol., 2008, 183, 63-75.
64. Yang, J.; Bardes, E.S.; Moore, J.D.; Brennan, J.; Powers, M.A.; Kornbluth, S., Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev., 1998, 12, 2131-2143. (Pubitemid 28348037)
65. Yang, J.; Kornbluth, S., All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners. Trends Cell Biol., 1999, 9, 207-210. (Pubitemid 29244129)
66. Hagting, A.; Jackman, M.; Simpson, K.; Pines, J., Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr. Biol., 1999, 9, 680-689. (Pubitemid 29332349)
67. Takizawa, C.G.; Morgan, D.O., Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr. Opin. Cell Biol., 2000, 12, 658-665.
68. Porter, L.A.; Donoghue, D.J., Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog. Cell Cycle Res., 2003, 5, 335-347.
69. Kong, M.; Barnes, E.A.; Ollendorff, V.; Donoghue, D.J., Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-cyclin interaction. EMBO J., 2000, 19, 1378-1388. (Pubitemid 30151033)
70. Hershko, A., Mechanisms and regulation of the degradation of cyclin B. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1999, 354, 1571-1575; discussion 1575-1576.
71. Chang, D.C.; Xu, N.; Luo, K.Q., Degradation of cyclin B is required for the onset of anaphase in Mammalian cells. J. Biol. Chem., 2003, 278, 37865-37873. (Pubitemid 37175315)
72. Shapiro, G.I., Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 2006, 24, 1770-1783. (Pubitemid 46628473)
73. Malumbres, M.; Barbacid, M., To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer, 2001, 1, 222-231. (Pubitemid 33741897)
74. Khatib, Z.A.; Matsushime, H.; Valentine, M.; Shapiro, D.N.; Sherr, C.J.; Look, A.T., Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 1993, 53, 5535-5541. (Pubitemid 23342180)
75. He, J.; Allen, J.R.; Collins, V.P.; Allalunis-Turner, M.J.; Godbout, R.; Day, R.S., 3rd; James, C.D., CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 1994, 54, 5804-5807. (Pubitemid 24375209)
76. Schmidt, E.E.; Ichimura, K.; Reifenberger, G.; Collins, V.P., CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 1994, 54, 6321-6324.
77. Sonoda, Y.; Yoshimoto, T.; Sekiya, T., Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene, 1995, 11, 2145-2149.
78. An, H.X.; Beckmann, M.W.; Reifenberger, G.; Bender, H.G.; Niederacher, D., Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol., 1999, 154, 113-118. (Pubitemid 29031618)
79. Perry, A.; Anderl, K.; Borell, T.J.; Kimmel, D.W.; Wang, C.H.; O'Fallon, J.R.; Feuerstein, B.G.; Scheithauer, B.W.; Jenkins, R.B., Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am. J. Clin. Pathol., 1999, 112, 801-809. (Pubitemid 30212511)
80. Wei, G.; Lonardo, F.; Ueda, T.; Kim, T.; Huvos, A.G.; Healey, J.H.; Ladanyi, M., CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int. J. Cancer, 1999, 80, 199-204. (Pubitemid 29001722)
81. Wunder, J.S.; Eppert, K.; Burrow, S.R.; Gokgoz, N.; Bell, R.S.; Andrulis, I.L., Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene, 1999, 18, 783-788. (Pubitemid 29080336)
82. Costello, J.F.; Plass, C.; Arap, W.; Chapman, V.M.; Held, W.A.; Berger, M.S.; Su Huang, H.J.; Cavenee, W.K., Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res., 1997, 57, 1250-1254. (Pubitemid 27152546)
83. Chilosi, M.; Doglioni, C.; Yan, Z.; Lestani, M.; Menestrina, F.; Sorio, C.; Benedetti, A.; Vinante, F.; Pizzolo, G.; Inghirami, G., Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am. J. Pathol., 1998, 152, 209-217. (Pubitemid 28028061)
84. Corcoran, M.M.; Mould, S.J.; Orchard, J.A.; Ibbotson, R.E.; Chapman, R.M.; Boright, A.P.; Platt, C.; Tsui, L.C.; Scherer, S.W.; Oscier, D.G., Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene, 1999, 18, 6271-6277.
85. Ortega, S.; Malumbres, M.; Barbacid, M., Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta, 2002, 1602, 73-87. (Pubitemid 34311901)
86. Lapenna, S.; Giordano, A., Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov., 2009, 8, 547-566.
87. Bayart, E.; Grigorieva, O.; Leibovitch, S.; Onclercq-Delic, R.; Amor-Gueret, M., A major role for mitotic CDC2 kinase inactivation in the establishment of the mitotic DNA damage checkpoint. Cancer Res., 2004, 64, 8954-8959. (Pubitemid 39665503)
88. Vassilev, L.T.; Tovar, C.; Chen, S.; Knezevic, D.; Zhao, X.; Sun, H.; Heimbrook, D.C.; Chen, L., Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 10660-10665. (Pubitemid 44078033)
89. Crasta, K.; Huang, P.; Morgan, G.; Winey, M.; Surana, U., Cdk1 regulates centrosome separation by restraining proteolysis of microtubule-associated proteins. EMBO J., 2006, 25, 2551-2563. (Pubitemid 44012237)
90. Ubersax, J.A.; Woodbury, E.L.; Quang, P.N.; Paraz, M.; Blethrow, J.D.; Shah, K.; Shokat, K.M.; Morgan, D.O., Targets of the cyclin-dependent kinase Cdk1. Nature, 2003, 425, 859-864. (Pubitemid 37351471)
91. Chen, H.; Huang, Q.; Dong, J.; Zhai, D.Z.; Wang, A.D.; Lan, Q., Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer, 2008, 8, 29.
92. Zhao, M.Y.; Auerbach, A.; D'Costa, A.M.; Rapoport, A.P.; Burger, A.M.; Sausville, E.A.; Stass, S.A.; Jiang, F.; Sands, A.M.; Aguilera, N.; Zhao, X.F., Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin. Cancer Res., 2009, 15, 1708-1720.
93. Dutta, A.; Chandra, R.; Leiter, L.M.; Lester, S., Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 5386-5390.
94. Mashal, R.D.; Lester, S.; Corless, C.; Richie, J.P.; Chandra, R.; Propert, K.J.; Dutta, A., Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res., 1996, 56, 4159-4163. (Pubitemid 26305010)
95. Kawamoto, H.; Koizumi, H.; Uchikoshi, T., Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am. J. Pathol., 1997, 150, 15-23. (Pubitemid 27027091)
96. Wang, A.; Yoshimi, N.; Ino, N.; Tanaka, T.; Mori, H., Overexpression of cyclin B1 in human colorectal cancers. J. Cancer Res. Clin. Oncol., 1997, 123, 124-127. (Pubitemid 27062538)
97. Kushner, J.; Bradley, G.; Young, B.; Jordan, R.C., Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J. Oral. Pathol. Med., 1999, 28, 77-81. (Pubitemid 29064508)
98. Murakami, H.; Furihata, M.; Ohtsuki, Y.; Ogoshi, S., Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch., 1999, 434, 153-158. (Pubitemid 29184993)
99. Soria, J.C.; Jang, S.J.; Khuri, F.R.; Hassan, K.; Liu, D.; Hong, W.K.; Mao, L., Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res., 2000, 60, 4000-4004. (Pubitemid 30636572)
100. Takeno, S.; Noguchi, T.; Kikuchi, R.; Uchida, Y.; Yokoyama, S.; Muller, W., Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer, 2002, 94, 2874-2881. (Pubitemid 34547686)
101. Wikman, H.; Kettunen, E.; Seppanen, J.K.; Karjalainen, A.; Hollmen, J.; Anttila, S.; Knuutila, S., Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene, 2002, 21, 5804-5813. (Pubitemid 35333015)
102. Koon, N.; Schneider-Stock, R.; Sarlomo-Rikala, M.; Lasota, J.; Smolkin, M.; Petroni, G.; Zaika, A.; Boltze, C.; Meyer, F.; Andersson, L.; Knuutila, S.; Miettinen, M.; El-Rifai, W., Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut, 2004, 53, 235-240. (Pubitemid 38125511)
103. Goga, A.; Yang, D.; Tward, A.D.; Morgan, D.O.; Bishop, J.M., Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med., 2007, 13, 820-827. (Pubitemid 47038193)
104. Musacchio, A.; Salmon, E.D., The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol., 2007, 8, 379-393. (Pubitemid 46643240)
105. Perez de Castro, I.; de Carcer, G.; Malumbres, M., A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis, 2007, 28, 899-912. (Pubitemid 47072171)
106. O'Connor, D.S.; Wall, N.R.; Porter, A.C.; Altieri, D.C., A p34(cdc2) survival checkpoint in cancer. Cancer Cell, 2002, 2, 43-54.
107. Schulze-Gahmen, U.; Kim, S.H., Structural basis for CDK6 activation by a virus-encoded cyclin. Nat. Struct. Biol., 2002, 9, 177-181. (Pubitemid 34171308)
108. Day, P.J.; Cleasby, A.; Tickle, I.J.; O'Reilly, M.; Coyle, J.E.; Holding, F.P.; McMenamin, R.L.; Yon, J.; Chopra, R.; Lengauer, C.; Jhoti, H., Crystal structure of human CDK4 in complex with a D-type cyclin. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 4166-4170.
109. Senderowicz, A.M., Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs, 1999, 17, 313-320. (Pubitemid 30037961)
110. Huwe, A.; Mazitschek, R.; Giannis, A., Small molecules as inhibitors of cyclin-dependent kinases. Angew. Chem. Int. Ed. Engl., 2003, 42, 2122-2138. (Pubitemid 36612925)
111. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E., Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 1992, 84, 1736-1740.
112. Bible, K.C.; Lensing, J.L.; Nelson, S.A.; Lee, Y.K.; Reid, J.M.; Ames, M.M.; Isham, C.R.; Piens, J.; Rubin, S.L.; Rubin, J.; Kaufmann, S.H.; Atherton, P.J.; Sloan, J.A.; Daiss, M.K.; Adjei, A.A.; Erlichman, C., Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin. Cancer Res., 2005, 11, 5935-5941. (Pubitemid 41170323)
113. Chen, R.; Keating, M.J.; Gandhi, V.; Plunkett, W., Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood, 2005, 106, 2513-2519. (Pubitemid 41510827)
114. Grendys, E.C., Jr.; Blessing, J.A.; Burger, R.; Hoffman, J., A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol., 2005, 98, 249-253. (Pubitemid 41019113)
115. Shah, M.A.; Kortmansky, J.; Motwani, M.; Drobnjak, M.; Gonen, M.; Yi, S.; Weyerbacher, A.; Cordon-Cardo, C.; Lefkowitz, R.; Brenner, B.; O'Reilly, E.; Saltz, L.; Tong, W.; Kelsen, D.P.; Schwartz, G.K., A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin. Cancer Res., 2005, 11, 3836-3845. (Pubitemid 40685604)
116. Whitlock, J.A.; Krailo, M.; Reid, J.M.; Ruben, S.L.; Ames, M.M.; Owen, W.; Reaman, G., Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. J. Clin. Oncol., 2005, 23, 9179-9186.
117. Dispenzieri, A.; Gertz, M.A.; Lacy, M.Q.; Geyer, S.M.; Fitch, T.R.; Fenton, R.G.; Fonseca, R.; Isham, C.R.; Ziesmer, S.C.; Erlichman, C.; Bible, K.C., Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica, 2006, 91, 390-393.
118. El-Rayes, B.F.; Gadgeel, S.; Parchment, R.; Lorusso, P.; Philip, P.A., A phase I study of flavopiridol and docetaxel. Invest New Drugs, 2006, 24, 305-310.
119. Morris, D.G.; Bramwell, V.H.; Turcotte, R.; Figueredo, A.T.; Blackstein, M.E.; Verma, S.; Matthews, S.; Eisenhauer, E.A., A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma. Sarcoma, 2006, 2006, 64374.
120. Byrd, J.C.; Lin, T.S.; Dalton, J.T.; Wu, D.; Phelps, M.A.; Fischer, B.; Moran, M.; Blum, K.A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L.J.; Johnson, A.J.; Lucas, D.M.; Heerema, N.A.; Lozanski, G.; Young, D.C.; Suarez, J.R.; Colevas, A.D.; Grever, M.R., Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007, 109, 399-404. (Pubitemid 46105932)
121. Fornier, M.N.; Rathkopf, D.; Shah, M.; Patil, S.; O'Reilly, E.; Tse, A.N.; Hudis, C.; Lefkowitz, R.; Kelsen, D.P.; Schwartz, G.K., Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin. Cancer Res., 2007, 13, 5841-5846. (Pubitemid 47583909)
122. Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D., Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poorrisk acute myelogenous leukemia. Clin. Cancer Res., 2007, 13, 4467-4473. (Pubitemid 47219715)
123. Ambrosini, G.; Seelman, S.L.; Qin, L.X.; Schwartz, G.K., The cyclindependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53- dependent manner. Cancer Res., 2008, 68, 2312-2320. (Pubitemid 351521805)
124. George, S.; Kasimis, B.S.; Cogswell, J.; Schwarzenberger, P.; Shapiro, G.I.; Fidias, P.; Bukowski, R.M., Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin. Lung Cancer, 2008, 9, 160-165. (Pubitemid 351880855)
125. Jackman, K.M.; Frye, C.B.; Hunger, S.P., Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatr. Blood Cancer, 2008, 50, 772-778. (Pubitemid 351354783)
126. Carvajal, R.D.; Tse, A.; Shah, M.A.; Lefkowitz, R.A.; Gonen, M.; Gilman- Rosen, L.; Kortmansky, J.; Kelsen, D.P.; Schwartz, G.K.; O'Reilly, E.M., A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology, 2009, 9, 404-409.
127. Phelps, M.A.; Lin, T.S.; Johnson, A.J.; Hurh, E.; Rozewski, D.M.; Farley, K.L.; Wu, D.; Blum, K.A.; Fischer, B.; Mitchell, S.M.; Moran, M.E.; Brooker-McEldowney, M.; Heerema, N.A.; Jarjoura, D.; Schaaf, L.J.; Byrd, J.C.; Grever, M.R.; Dalton, J.T., Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 2009, 113, 2637-2645.
128. Rathkopf, D.; Dickson, M.A.; Feldman, D.R.; Carvajal, R.D.; Shah, M.A.; Wu, N.; Lefkowitz, R.; Gonen, M.; Cane, L.M.; Dials, H.J.; Winkelmann, J.L.; Bosl, G.J.; Schwartz, G.K., Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin. Cancer Res., 2009, 15, 7405-7411.
129. Yang, X.; Zhao, X.; Phelps, M.A.; Piao, L.; Rozewski, D.M.; Liu, Q.; Lee, L.J.; Marcucci, G.; Grever, M.R.; Byrd, J.C.; Dalton, J.T.; Lee, R.J., A novel liposomal formulation of flavopiridol. Int. J. Pharm., 2009, 365, 170-174.
130. Dickson, M.A.; Shah, M.A.; Rathkopf, D.; Tse, A.; Carvajal, R.D.; Wu, N.; Lefkowitz, R.A.; Gonen, M.; Cane, L.M.; Dials, H.J.; Schwartz, G.K., A phase I clinical trial of FOLFIRI in combination with the pan-cyclindependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother. Pharmacol., 2010, 66, 1113-1121.
131. Fekrazad, H.M.; Verschraegen, C.F.; Royce, M.; Smith, H.O.; Chyi Lee, F.; Rabinowitz, I., A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. Am. J. Clin. Oncol., 2010, 33, 393-397.
132. Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A., Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood, 2011.
133. Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolanos- Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J., Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk. Res., 2010, 34, 877-882.
134. Kim, K.S.; Sack, J.S.; Tokarski, J.S.; Qian, L.; Chao, S.T.; Leith, L.; Kelly, Y.F.; Misra, R.N.; Hunt, J.T.; Kimball, S.D.; Humphreys, W.G.; Wautlet, B.S.; Mulheron, J.G.; Webster, K.R., Thio- and oxoflavopiridols, cyclindependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem., 2000, 43, 4126-4134.
135. Schoepfer, J.; Fretz, H.; Chaudhuri, B.; Muller, L.; Seeber, E.; Meijer, L.; Lozach, O.; Vangrevelinghe, E.; Furet, P., Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem., 2002, 45, 1741-1747. (Pubitemid 34415369)
136. Lee, J.; Park, T.; Jeong, S.; Kim, K.H.; Hong, C., 3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2007, 17, 1284-1287.
137. Joshi, K.S.; Rathos, M.J.; Joshi, R.D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S., In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol. Cancer Ther., 2007, 6, 918-925. (Pubitemid 46554561)
138. Joshi, K.S.; Rathos, M.J.; Mahajan, P.; Wagh, V.; Shenoy, S.; Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H.H.; Sharma, S., P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol. Cancer Ther., 2007, 6, 926-934. (Pubitemid 46554562)
139. Raje, N.; Hideshima, T.; Mukherjee, S.; Raab, M.; Vallet, S.; Chhetri, S.; Cirstea, D.; Pozzi, S.; Mitsiades, C.; Rooney, M.; Kiziltepe, T.; Podar, K.; Okawa, Y.; Ikeda, H.; Carrasco, R.; Richardson, P.G.; Chauhan, D.; Munshi, N.C.; Sharma, S.; Parikh, H.; Chabner, B.; Scadden, D.; Anderson, K.C., Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia, 2009, 23, 961-970.
140. Manohar, S.M.; Rathos, M.J.; Sonawane, V.; Rao, S.V.; Joshi, K.S., Cyclindependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk. Res., 2011.
141. Sayle, K.L.; Bentley, J.; Boyle, F.T.; Calvert, A.H.; Cheng, Y.; Curtin, N.J.; Endicott, J.A.; Golding, B.T.; Hardcastle, I.R.; Jewsbury, P.; Mesguiche, V.; Newell, D.R.; Noble, M.E.; Parsons, R.J.; Pratt, D.J.; Wang, L.Z.; Griffin, R.J., Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg. Med. Chem. Lett., 2003, 13, 3079-3082. (Pubitemid 36993641)
142. Arris, C.E.; Boyle, F.T.; Calvert, A.H.; Curtin, N.J.; Endicott, J.A.; Garman, E.F.; Gibson, A.E.; Golding, B.T.; Grant, S.; Griffin, R.J.; Jewsbury,
143. Seong, Y.S.; Min, C.; Li, L.; Yang, J.Y.; Kim, S.Y.; Cao, X.; Kim, K.; Yuspa, S.H.; Chung, H.H.; Lee, K.S., Characterization of a novel cyclindependent kinase 1 inhibitor, BMI-1026. Cancer Res., 2003, 63, 7384-7391. (Pubitemid 37413480)
144. Huang, S.; Li, R.; Connolly, P.J.; Emanuel, S.; Middleton, S.A., Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 4818-4821. (Pubitemid 44175860)
145. Chu, X.J.; DePinto, W.; Bartkovitz, D.; So, S.S.; Vu, B.T.; Packman, K.; Lukacs, C.; Ding, Q.; Jiang, N.; Wang, K.; Goelzer, P.; Yin, X.; Smith, M.A.; Higgins, B.X.; Chen, Y.; Xiang, Q.; Moliterni, J.; Kaplan, G.; Graves, B.; Lovey, A.; Fotouhi, N., Discovery of [4-Amino-2-(1- methanesulfonylpiperidin-4- ylamino)pyrimidin-5-yl](2,3-diflu oro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J. Med. Chem., 2006, 49, 6549-6560. (Pubitemid 44657449)
146. DePinto, W.; Chu, X.J.; Yin, X.; Smith, M.; Packman, K.; Goelzer, P.; Lovey, A.; Chen, Y.; Qian, H.; Hamid, R.; Xiang, Q.; Tovar, C.; Blain, R.; Nevins, T.; Higgins, B.; Luistro, L.; Kolinsky, K.; Felix, B.; Hussain, S.; Heimbrook, D., In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther., 2006, 5, 2644-2658. (Pubitemid 44848991)
147. Diab, S.; Eckhardt, S.; Tan, A.; Frenette, G.; Gore, L.; Depinto, W.; Grippo, J.; DeMario, M.; Mikulski, S.; Papadimitrakopoulou, S., A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs). J. Clin. Oncol., 2007, 25, 3528.
148. Byth, K.F.; Thomas, A.; Hughes, G.; Forder, C.; McGregor, A.; Geh, C.; Oakes, S.; Green, C.; Walker, M.; Newcombe, N.; Green, S.; Growcott, J.; Barker, A.; Wilkinson, R.W., AZD5438, a potent oral inhibitor of cyclindependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol. Cancer Ther., 2009, 8, 1856-1866.
149. Kuo, G.H.; Deangelis, A.; Emanuel, S.; Wang, A.; Zhang, Y.; Connolly, P.J.; Chen, X.; Gruninger, R.H.; Rugg, C.; Fuentes-Pesquera, A.; Middleton, S.A.; Jolliffe, L.; Murray, W.V., Synthesis and identification of [1,3,5]triazinepyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors. J. Med. Chem., 2005, 48, 4535-4546. (Pubitemid 40993415)
150. Jacquemard, U.; Dias, N.; Lansiaux, A.; Bailly, C.; Loge, C.; Robert, J.M.; Lozach, O.; Meijer, L.; Merour, J.Y.; Routier, S., Synthesis of 3,5-bis(2- indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorg. Med. Chem., 2008, 16, 4932-4953. (Pubitemid 351635769)
151. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J.J.; Donella-Deana, A.; Pinna, L.; Letham, D.S.; Kato, J.; Detivaud, L.; Leclerc, S.; et al., Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem., 1994, 224, 771-786. (Pubitemid 24282865)
152. Abraham, R.T.; Acquarone, M.; Andersen, A.; Asensi, A.; Belle, R.; Berger, F.; Bergounioux, C.; Brunn, G.; Buquet-Fagot, C.; Fagot, D.; et al., Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol. Cell, 1995, 83, 105-120.
153. De Azevedo, W.F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S.H., Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem., 1997, 243, 518-526. (Pubitemid 27060442)
154. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J.P.; Blow, J.J.; Inagaki, N.; Inagaki, M.; Delcros, J.G.; Moulinoux, J.P., Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 1997, 243, 527-536. (Pubitemid 27060443)
155. Gray, N.S.; Wodicka, L.; Thunnissen, A.M.; Norman, T.C.; Kwon, S.; Espinoza, F.H.; Morgan, D.O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.H.; Lockhart, D.J.; Schultz, P.G., Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science, 1998, 281, 533-538. (Pubitemid 28357362)
156. Krystof, V.; Lenobel, R.; Havlicek, L.; Kuzma, M.; Strnad, M., Synthesis and biological activity of olomoucine II. Bioorg. Med. Chem. Lett., 2002, 12, 3283-3286. (Pubitemid 35251910)
157. Krystof, V.; McNae, I.W.; Walkinshaw, M.D.; Fischer, P.M.; Muller, P.; Vojtesek, B.; Orsag, M.; Havlicek, L.; Strnad, M., Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol. Life Sci., 2005, 62, 1763-1771. (Pubitemid 41176057)
158. Holcakova, J.; Tomasec, P.; Bugert, J.J.; Wang, E.C.; Wilkinson, G.W.; Hrstka, R.; Krystof, V.; Strnad, M.; Vojtesek, B., The inhibitor of cyclindependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir. Chem. Chemother., 2010, 20, 133-142.
159. Davies, T.G.; Bentley, J.; Arris, C.E.; Boyle, F.T.; Curtin, N.J.; Endicott, J.A.; Gibson, A.E.; Golding, B.T.; Griffin, R.J.; Hardcastle, I.R.; Jewsbury, P.; Johnson, L.N.; Mesguiche, V.; Newell, D.R.; Noble, M.E.; Tucker, J.A.; Wang, L.; Whitfield, H.J., Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol., 2002, 9, 745-749.
160. Hardcastle, I.R.; Arris, C.E.; Bentley, J.; Boyle, F.T.; Chen, Y.; Curtin, N.J.; Endicott, J.A.; Gibson, A.E.; Golding, B.T.; Griffin, R.J.; Jewsbury, P.; Menyerol, J.; Mesguiche, V.; Newell, D.R.; Noble, M.E.; Pratt, D.J.; Wang, L.Z.; Whitfield, H.J., N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J. Med. Chem., 2004, 47, 3710-3722. (Pubitemid 38900338)
161. Meijer, L., Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol., 1996, 6, 393-397. (Pubitemid 26315904)
162. Yoshida, M.; Usui, T.; Tsujimura, K.; Inagaki, M.; Beppu, T.; Horinouchi, S., Biochemical differences between staurosporine-induced apoptosis and premature mitosis. Exp. Cell Res., 1997, 232, 225-239. (Pubitemid 27194034)
163. Chen, X.; Lowe, M.; Keyomarsi, K., UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene, 1999, 18, 5691-5702. (Pubitemid 29497604)
164. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D.W.; Gussio, R.; Sausville, E.A.; Meijer, L.; Kunick, C., Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem., 1999, 42, 2909-2919. (Pubitemid 29370435)
165. Sielecki, T.M.; Boylan, J.F.; Benfield, P.A.; Trainor, G.L., Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem., 2000, 43, 1-18. (Pubitemid 30055758)
166. Han, R., Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells, 1994, 12, 53-63. (Pubitemid 24045786)
167. Hoessel, R.; Leclerc, S.; Endicott, J.A.; Nobel, M.E.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L., Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol., 1999, 1, 60-67. (Pubitemid 129495012)
168. Raffa, D.; Maggio, B.; Cascioferro, S.; Raimondi, M.V.; Daidone, G.; Plescia, S.; Schillaci, D.; Cusimano, M.G.; Titone, L.; Colomba, C.; Tolomeo, M., N-(indazolyl)benzamido derivatives as CDK1 inhibitors: design, synthesis, biological activity, and molecular docking studies. Arch. Pharm. (Weinheim), 2009, 342, 265-273.
169. Xiong, X.; Zhang, Y.; Gao, X.; Dong, Z.; Li, L.; Ji, C.; Fu, L.; Luo, X.; Liu, H.; Mei, C., B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest. Invest New Drugs, 2010, 28, 26-34.
170. Misra, R.N.; Xiao, H.; Rawlins, D.B.; Shan, W.; Kellar, K.A.; Mulheron, J.G.; Sack, J.S.; Tokarski, J.S.; Kimball, S.D.; Webster, K.R., 1HPyrazolo[ 3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues. Bioorg. Med. Chem. Lett., 2003, 13, 2405-2408. (Pubitemid 36724992)
171. Huang, S.; Lin, R.; Yu, Y.; Lu, Y.; Connolly, P.J.; Chiu, G.; Li, S.; Emanuel, S.L.; Middleton, S.A., Synthesis of 3-(1H-benzimidazol-2-yl)-5- isoquinolin- 4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor. Bioorg. Med. Chem. Lett., 2007, 17, 1243-1245. (Pubitemid 46240855)
172. Lin, R.; Connolly, P.J.; Lu, Y.; Chiu, G.; Li, S.; Yu, Y.; Huang, S.; Li, X.; Emanuel, S.L.; Middleton, S.A.; Gruninger, R.H.; Adams, M.; Fuentes- Pesquera, A.R.; Greenberger, L.M., Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents. Bioorg. Med. Chem. Lett., 2007, 17, 4297-4302. (Pubitemid 47021391)
173. Byth, K.F.; Culshaw, J.D.; Green, S.; Oakes, S.E.; Thomas, A.P., Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 2245-2248. (Pubitemid 38481398)
174. Byth, K.F.; Geh, C.; Forder, C.L.; Oakes, S.E.; Thomas, A.P., The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclindependent kinase inhibitor. Mol. Cancer Ther., 2006, 5, 655-664.
175. Cai, D.; Byth, K.F.; Shapiro, G.I., AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res., 2006, 66, 435-444. (Pubitemid 43166052)
176. Lin, R.; Connolly, P.J.; Huang, S.; Wetter, S.K.; Lu, Y.; Murray, W.V.; Emanuel, S.L.; Gruninger, R.H.; Fuentes-Pesquera, A.R.; Rugg, C.A.; Middleton, S.A.; Jolliffe, L.K., 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J. Med. Chem., 2005, 48, 4208-4211. (Pubitemid 40884921)
177. Kojima, K.; Shimanuki, M.; Shikami, M.; Andreeff, M.; Nakakuma, H., Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci., 2009, 100, 1128-1136.
178. Payton, M.; Chung, G.; Yakowec, P.; Wong, A.; Powers, D.; Xiong, L.; Zhang, N.; Leal, J.; Bush, T.L.; Santora, V.; Askew, B.; Tasker, A.; Radinsky, R.; Kendall, R.; Coats, S., Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res., 2006, 66, 4299-4308.
179. Kawanishi, N.; Sugimoto, T.; Shibata, J.; Nakamura, K.; Masutani, K.; Ikuta, M.; Hirai, H., Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg. Med. Chem. Lett., 2006, 16, 5122-5126. (Pubitemid 44247696)
180. Hirai, H.; Takahashi-Suziki, I.; Shimomura, T.; Fukasawa, K.; Machida, T.; Takaki, T.; Kobayashi, M.; Eguchi, T.; Oki, H.; Arai, T.; Ichikawa, K.; Hasako, S.; Kodera, T.; Kawanishi, N.; Nakatsuru, Y.; Kotani, H.; Iwasawa, Y., Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs, 2010.
181. Popowycz, F.; Fournet, G.; Schneider, C.; Bettayeb, K.; Ferandin, Y.; Lamigeon, C.; Tirado, O.M.; Mateo-Lozano, S.; Notario, V.; Colas, P.; Bernard, P.; Meijer, L.; Joseph, B., Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)- roscovitine analogue. J. Med. Chem., 2009, 52, 655-663.
182. Parry, D.; Guzi, T.; Shanahan, F.; Davis, N.; Prabhavalkar, D.; Wiswell, D.; Seghezzi, W.; Paruch, K.; Dwyer, M.P.; Doll, R.; Nomeir, A.; Windsor, W.; Fischmann, T.; Wang, Y.; Oft, M.; Chen, T.; Kirschmeier, P.; Lees, E.M., Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther., 2010, 9, 2344-2353.
183. Motwani, M.; Delohery, T.M.; Schwartz, G.K., Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 1999, 5, 1876-1883. (Pubitemid 29334472)
184. Liu, G.; Gandara, D.R.; Lara, P.N., Jr.; Raghavan, D.; Doroshow, J.H.; Twardowski, P.; Kantoff, P.; Oh, W.; Kim, K.; Wilding, G., A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin. Cancer Res., 2004, 10, 924-928. (Pubitemid 38198891)
185. Burdette-Radoux, S.; Tozer, R.G.; Lohmann, R.C.; Quirt, I.; Ernst, D.S.; Walsh, W.; Wainman, N.; Colevas, A.D.; Eisenhauer, E.A., Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs, 2004, 22, 315-322. (Pubitemid 39012571)
186. Grendys, E.C., Jr.; Blessing, J.A.; Burger, R.; Hoffman, J., A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol., 2005, 98, 249-253. (Pubitemid 41019113)